Using the Zebrafish Larval Model of Infection to Investigate Antibiotic Efficacy and Combination Treatments Against Staphylococcus aureus

Amy K Tooke; Simon J Foster

doi:10.1007/978-1-0716-3981-8_1

Using the Zebrafish Larval Model of Infection to Investigate Antibiotic Efficacy and Combination Treatments Against Staphylococcus aureus

Methods Mol Biol. 2024:2833:1-10. doi: 10.1007/978-1-0716-3981-8_1.

Authors

Amy K Tooke^{1

2}, Simon J Foster^{3

4

5}

Affiliations

¹ School of Biosciences, University of Sheffield, Sheffield, UK.
² Newcastle University Biosciences Institute, Newcastle upon Tyne, UK.
³ School of Biosciences, University of Sheffield, Sheffield, UK. [email protected].
⁴ Florey Institute, University of Sheffield, Sheffield, UK. [email protected].
⁵ Krebs Institute, University of Sheffield, Sheffield, UK. [email protected].

PMID: 38949695
DOI: 10.1007/978-1-0716-3981-8_1

Abstract

There is an increasing need for new treatment regimens to combat antibiotic-resistant strains of bacteria. Staphylococcus aureus is a clinically important, opportunist pathogen that has developed resistance to a range of antibiotics. The zebrafish larval model of systemic disease has been increasingly utilized to elucidate S. aureus virulence mechanisms and host-pathogen interactions. Here, we outline how this model can be used to investigate the effects of different antibiotics alone and in combination against S. aureus.

Keywords: Antibiotics; Antimicrobials; Combination treatment; Drug screening; In vivo model; Infection; Staphylococcus aureus; Zebrafish.

MeSH terms

Animals
Anti-Bacterial Agents* / pharmacology
Anti-Bacterial Agents* / therapeutic use
Disease Models, Animal*
Drug Therapy, Combination
Host-Pathogen Interactions / drug effects
Larva* / drug effects
Larva* / microbiology
Microbial Sensitivity Tests
Staphylococcal Infections* / drug therapy
Staphylococcal Infections* / microbiology
Staphylococcus aureus* / drug effects
Zebrafish* / microbiology

Substances

Anti-Bacterial Agents